Next Pharmaceuticals Study Shows Citrofen Eases Joint Pain And Lowers Weight
Published: Feb 13, 2007
CARLSBAD, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today the results of a clinical study on their new patented ingredient Citrofen™ that demonstrated the new patented formulation cuts stiffness in half for participants who had knee osteoarthritis and it boosted comfort and mobility by up to fifty percent. These results were obtained in a double-blind placebo-controlled clinical trial with eighty overweight and normal weight subjects. The clinical trial concluded that Citrofen™ has multiple benefits in people with knee osteoarthritis including significant loss of weight. In the US, some 70 million people suffer from joint ailments; most of the time osteoarthritis attacks the knees and/or hips.